We review the recent changes in diagnostic criteria of gestational diabetes mellitus (GDM), describe problems with maintaining and monitoring adequate blood glucose, especially in type 1 diabetes, and provide a brief overview of the currently approved glucose-lowering therapies in pregnancy.
INTRODUCTION
Diabetes is one of the most common chronic diseases, affecting hundreds of millions of people worldwide [1, 2] . There are various forms of diabetes, with different pathogenesis and clinical pictures. Their common denominator is hyperglycaemia, which results from impaired insulin production, action, or both, and may lead to chronic complications and a shortening of the patient's life span [3] [4] [5] .
The current classification, published in the late 1990s by WHO, distinguishes two major forms of diabetes -type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) [6] . T1DM is related to the autoimmune destruction of the b cells and abolishment of insulin secretion, and it is usually diagnosed in children, adolescents, as well as young adults [3] . T1DM patients constitute about 5-10% of all individuals with diabetes. This diabetes type requires insulin therapy for life. T2DM is associated with both insulin resistance and impaired insulin secretion. It is the most prevalent form of diabetes, comprising approximately 90% of the cases, and it is commonly accompanied by obesity [1, 3] . T2DM is generally a disease of middle-aged and elderly individuals; however, more and more frequently, it affects younger adults and adolescents [3] . The third group of diabetes is referred to in the WHO classification as the 'other specific types' of diabetes, which result from known causes, such as single-gene mutations affecting insulin secretion or action, endocrinopathies, some medications and toxic agents, pancreatitis or pancreatectomy [6] . The number of women of reproductive age that are affected by T1DM, T2DM and other types of diabetes is growing, as is the number of pregnancies complicated by diabetes preceding conception [7] [8] [9] . In these cases, we refer to the women as having pregnancies complicated by pre-gestational diabetes. However, in most cases of diabetes-complicated pregnancy, diabetes is diagnosed for the first time during pregnancy and usually remits after delivery. This type of disease is called gestational diabetes mellitus (GDM) [6] . It is estimated that GDM may affect even over 10% of pregnancies, depending on the specific population, as well as criteria and algorithm used [10] [11] [12] [13] [14] [15] . GDM develops in women with environmental and genetic risk factors whose b-cell apparatus is not able to respond to growing insulin resistance related to, among other factors, changes in the secretion of placental hormones, such as lactogen, cortisol, oestrogens or progesterone [16] . There are some defined clinical risk factors of GDM, including age above 35 years, obesity, earlier deliveries of macrosomic babies or stillbirths, polycystic ovary syndrome, family history of T2DM and GDM in previous pregnancies [17] . Hyperglycaemia in overt, pre-gestational diabetes, as well as in GDM, has serious adverse impact on the clinical course of pregnancy and it is associated with increased risk of maternal and foetal complications [18] [19] [20] [21] . These include preeclampsia, hydramnios, perinatal trauma, stillbirths, macrosomia, congenital defects, neonatal hyperbilirubinaemia and hypoglycaemia, infant respiratory distress syndrome and other problems [18] [19] [20] [21] . The risk of these adverse outcomes is closely related to the level of hyperglycaemia, and strict glycaemic control can effectively reduce their burden [21] . Thus, it is extremely important to inform physicians of all specialties who are involved in the clinical care of pregnant women with diabetes complicating their gestation about recent changes in guidelines and medical practice.
NEW 2013 WHO DIAGNOSTIC CRITERIA: A STEP TOWARDS WORLDWIDE UNIFICATION OF GESTATIONAL DIABETES MELLITUS DIAGNOSIS
The term 'gestational diabetes' was introduced for the first time in the 1950s [22, 23] , and in the 1960s, the first diagnostic criteria were proposed [24] . However, over several decades, different diagnostic thresholds and algorithms were used around the world. For example, according to the well established WHO criteria published in 1999 [6] , GDM was diagnosed, when a 'standard' 75 g oral glucose tolerance test (OGTT), performed typically between the 24th and 28th week of gestation (fasting or 2-h value), met criteria of either overt diabetes or impaired glucose tolerance outside of pregnancy (Table 1) . These recommendations were adopted [25] , sometimes with certain modifications, in many parts of the world. Meanwhile, the American Diabetes Association (ADA) recommended a twostep diagnostic approach [26] . An initial screening (without a requirement for the patient to be in fasting state) with a 50 g glucose load test (GLT), was followed in patients testing positive by a 100 g, 3-h OGTT. This approach was directly derived from the historically first (1964) algorithm of O'Sullivan and Mahan [24] , reiterated in 1979 by the influential guidelines of the National Diabetes Data Group [27] , with tightened cut-off values proposed by Carpenter and Coustan [28] ( Table 1 ). The discussion about GDM criteria gained new momentum after the publication of the HAPO study [29] . This large observational study examined pregnancy outcomes in more than 25 000 women in several countries and ethnic groups. It revealed a linear relationship between the risk of adverse pregnancy outcomes and maternal blood glucose level. It had a continuous form, without an inflexion point or obvious risk threshold, even in the blood glucose range previously considered clinically normal. The study prompted an international effort to modify existing clinical guidelines, under the auspices of the International Association of Diabetes and Pregnancy Study Groups (IADPSG). A consensus proposal of the new GDM criteria was published in 2010 [30] .
KEY POINTS
After the publication of the HAPO study, the International Association of Diabetes and Pregnancy Study Groups issued recommendations on the diagnosis and classification of hyperglycaemia in pregnancy, subsequently endorsed by the American Diabetes Association and WHO; however, they are still a subject of debate due to expected rise in prevalence of GDM, additional costs and insufficient evidence for benefits from randomized controlled studies. Improvement in diabetes care helped many women to achieve stringent glycaemic goals during pregnancy complicated by diabetes; however, in T1DM, the prevalence of macrosomia remains high, even in cohorts with very good metabolic control.
The list of possible future steps to lower the prevalence of macrosomia includes changing the current guidelines for glycaemic control in pre-gestational diabetes and introducing new monitoring tools.
Human recombinant insulins and some short and longacting insulin analogues remain the only approved glucose-lowering pharmacotherapy in pregnancy complicated by diabetes.
GDM would be diagnosed with a 75 g OGTT, with glucose assayed at fasting, and after 1 and 2 h. The new, one-step diagnostic algorithm was promptly endorsed by the ADA in its 2011 practice guidelines [31] ; however, the American College of Obstetrics and Gynecology (ACOG) continued to recommend a two-step approach [32 & ]. Subsequently, in 2013, the WHO modified its diagnostic criteria for hyperglycaemia in pregnancy, changing them in line with the IADPSG proposal [33 && ]. A very important change from the 1999 guidelines, inspired by the IADPSG consensus, was that GDM designation is now limited to only mild forms of hyperglycaemia. According to the new diagnostic criteria, diabetes first diagnosed in pregnancy (typically at the first prenatal visit or between the 24-28th week of gestation) is considered 'diabetes in pregnancy' when it meets the general diagnostic WHO criteria for diabetes outside of pregnancy: plasma blood glucose at least 7.0 mmol/l at fasting or at least 11.1 mmol/l in 2 h post-75 g OGTT, or at least 11.1 mmol/l random glucose accompanied by diabetes symptoms. GDM is now diagnosed when fasting glucose is 5.1-6.9 mmol/l, or when it is above 10.0 mmol/l 1 h post-75 g OGTT (there is no upper limit, since no criterion for diabetes in pregnancy based on 1-h post-OGTT glucose exists), or when 2-h post-OGTT glucose is 8.5-11.0 mmol/l (it is enough to fulfil just one of these three criteria for GDM diagnosis). This distinction between mild gestational diabetes and diabetes in pregnancy not only emphasizes differences in the severity of disease, risk of adverse outcomes and therapeutic approach (diabetes in pregnancy practically always requires insulin), but also suggests that the latter has other causes than just the pregnancy and is likely T1DM or T2DM, or possibly an 'other specific type', the diagnosis of which coincides with pregnancy. Whereas diabetes in pregnancy is usually associated with persisting abnormalities of glucose metabolism after delivery, GDM typically resolves postpartum, although it constitutes a risk factor of T1DM or T2DM in the further future. Therefore, pregnancy is the key component cause of GDM, whereas for diabetes in pregnancy, it is more a co-existing factor rather than a cause.
As of 2014, the ADA does not endorse the distinction between diabetes in pregnancy and GDM [34 & ]. Instead, it recommends that diabetes diagnosed in the first trimester (using the standard criteria) should be considered 'overt diabetes', implying its pre-gestational origin. In its 2014 guidelines, ADA again recommends, as an alternative to the onestep IADPSG procedure, a two-step algorithm with Carpenter-Coustan or O'Sullivan-Mahan/National Diabetes Data Group (NDDG) cut-offs [34 & ]. This decision was made exactly 50 years after the publication of the paper by O'Sullivan and Mahan, and was based on conclusions from the National Institutes of Health Consensus Development Conference [35 & ]. The objection to the new definition of GDM was primarily based upon the fact that the IADPSG criteria result in an increase in prevalence of GDM that is between two and threefold, incurring additional healthcare costs, financial and psychosocial burden on patients, without existing evidence from intervention studies that treatment of additional cases of GDM improves clinical outcomes. As a consequence, the ADA in its 2014 standards of care recommends either a one-step or a two-step algorithm, with a choice of three cut-offs in GLT in the latter (the most common 7.8 mmol/l, along with 7.5 and 7.2 mmol/l, supported by the ACOG Practice Bulletin [32 & ]) and two sets of criteria for the 100 g OGTT, which altogether gives seven ways to diagnose GDM. Worldwide acceptance of the new WHO criteria, although -in the opinion of the authors -desirable, is, therefore, unlikely.
Although it has not yet been proven in an experimental design that the new definition of GDM is associated with clinical benefits, rejection of the IADPSG criteria effectively leaves a large group of women with clearly elevated risk of complications without any tailored intervention, ignoring very persuasive results of a large, meticulously designed epidemiological study. Cost-effectiveness analyses, based on the currently available data, show favourable incremental cost-utility ratio of the new GDM-screening algorithm [36, 37] .
HIGH PREVALENCE OF MACROSOMIA IN TYPE 1 DIBETES MELLITUS-COMPLICATED PREGNANCY IN SPITE OF IMPROVEMENT IN GLYCAEMIC CONTROL: IS THERE NEED FOR CHANGES IN RECOMMENDATIONS?
Although there is a general consensus around the world that strict criteria of glycaemic control should be implemented during pregnancy complicated by diabetes in order to reduce maternal and foetal adverse outcomes, there are some differences between the published guidelines. For example, in its 2009 recommendations, the International Diabetes Federation (IDF) suggests an optimal preconception glycated haemoglobin A1c (HbA1c) level of below 7.0% in women treated with insulin or below 6.5% in other women with pre-gestational diabetes [38] . Women with HbA1c above 8.0% should be discouraged from getting pregnant. The ADA recommends HbA1c below 7.0% before planned pregnancy in diabetic patients [34 & ] and the United Kingdom-based National Institute for Health and Clinical Excellence (NICE) recommends HbA1c below 6.1%, whereas patients with HbA1c above 10.0% should be strongly advised to avoid pregnancy [25] . Even more stringent glycaemic control is recommended during pregnancy. ADA advises that HbA1c be maintained below 6.0% in pre-gestational diabetes, with self-monitored glucose level of 3.3-5.4 mmol/l before meal, during bedtime and at night; and 5.4-7.1 mmol/l peak postprandial. Interestingly, in GDM, the targets are different: before meal 5.3 mmol/l or less, and 1 and 2 h after meal 7.8 and 6.7 mmol/l or less, respectively [34 & ]. The NICE guidelines recommend that in all women with pregnancies complicated by diabetes (including GDM), the target preprandial glucose be between 3.5 and 5.9 mmol/l and 1-h postprandial glucose below 7.8 mmol/l ( Table 2 ) [25] .
Over the past two decades, new tools, such as short and long-acting insulin analogues, personal pumps, precise glucose meters and continuous glucose-monitoring systems have become available for physicians treating diabetes complicating pregnancy. These developments were accompanied by nationwide or local educational programmes that included, among others, education about the problem of pregnancy planning in pre-gestational diabetes. There is evidence from several populations that even in T1DM, which constitutes a particular challenge for clinicians, general improvement in glycaemic control has been observed [39] [40] [41] . In spite of this, there is very little evidence for the reduction of the most common neonatal outcome of diabetes-complicated pregnancy -macrosomia 40, 42] . Macrosomia is related to an increased risk of caesarean delivery, damage to the birth canal and injury to the baby during vaginal labour. Infant complications also include neonatal hypoglycaemia, respiratory distress syndrome and jaundice, as well as risk of obesity and metabolic abnormalities later in life. It was reported that even in T1DM cohorts with excellent glycaemic control, the prevalence of macrosomia remains as high as 20-40% [41, 42] . The reason for this observation remains unclear and several explanations have been suggested. One of them points to the limitations of HbA1c as a tool for monitoring glycaemic control to detect short hyperglycaemic episodes. Another possible explanation is that this problem could be related to excessive gestational weight gain in pregnancy complicated by T1DM [43] . One should also consider lowering the current criteria for glycaemic control, as the HbA1c level of 6.0% is substantially higher than in the population of healthy pregnant women. In our recent analysis, we pointed to thirdtrimester HbA1c as a major independent determinant of birth weight in T1DM-complicated pregnancy [44] . We also described a linear relationship between the HbA1c level and the prevalence of macrosomia [44] . Thus, a body of evidence indicates that the current criteria for glycaemic control in pregnancy should be reconsidered. Moreover, new markers of glycaemic control, for example, 1,5-anhydroglucitol, have been suggested, and they seem to constitute an alternative to HbA1c in the future [45] . More attention should be paid to gestational weight gain, particularly in patients on insulin pumps, who are particularly prone to excessive weight increase [46] .
PHARMACOLOGICAL TREATMENT OF DIABETES DURING PREGNANCY
In some GDM cases, diet alone is sufficient to achieve glycaemic targets; however, in many other patients with GDM, as well as in all women with pre-gestational diabetes, pharmacotherapy is necessary. The key component of pharmacological diabetes management during pregnancy is insulin therapy. There are two major methods that can be used -multiple daily injection (MDI) therapy by insulin pens or continuous subcutaneous insulin infusion (CSII) by personal pumps. Recombinant human insulin has been widely used in pregnancies complicated by diabetes for the past three decades [47] . Two short-acting analogues, lyspro and as part, used as a prandial insulin, showed effectiveness and safety similar to that of human insulin in many clinical observations, the latter also in a randomized clinical trial [48] [49] [50] [51] . The third short-acting analogue, insulin glulisine, has not been sufficiently examined in pregnant women [52] . Additionally, long-acting insulin analogues, glargine and detemir, were proved effective and well tolerated in observational studies in pregnant T1DM and GDM women [53, 54] . A recently published randomized clinical trial in T1DM women treated with detemir showed non-inferior maternal pregnancy outcomes as compared to a human long-acting insulin [55] .
In spite of the encouraging data from two randomized controlled studies that examined sulphonylurea and metformin use in GDM, no oral hypoglycaemic agent has been approved for clinical use during pregnancy by the regulatory agencies. A novel problem that will be encountered with increasing frequency is related to pregnant women with prior diagnosis of monogenic diabetes. Monogenic forms account for a few percent of all diabetes cases, which corresponds to several millions of patients in Europe alone, including many women of reproductive age. Sulphonylurea was proven to be very effective and well tolerated in some monogenic forms related to impaired insulin secretion, such as hepatocyte nuclear factor 1 alpha (HNF1A) maturity onset diabetes of the young and permanent neonatal diabetes mellitus (PNDM), associated with mutations in genes encoding adenosine triphosphate (ATP)-dependent potassium channel subunits [56, 57] . Recently, two cases of pregnant women with Kir6.2-related PNDM treated by sulphonylurea have been reported. Sulphonylurea use during the entire pregnancy did not result in developmental abnormalities and both pregnancies ended with a delivery of healthy newborns [58] . Nevertheless, further research is needed before this therapy is recommended in this or other forms of monogenic diabetes during pregnancy.
CONCLUSION
The number of pregnancies complicated by diabetes is growing worldwide. This constitutes a large healthcare, organizational and economic problem. In spite of substantial progress in diabetes care, a lot has yet to be done to reduce the prevalence of maternal and foetal complications. Pregnant women should be properly tested for GDM in order to receive the necessary treatment. The new, stringent diagnostic criteria (IADPSG and WHO 2013) are increasingly accepted; however, a strong opposition persists, and in some parts of the world, notably United States, local recommendations exist. The major concern about the new definition of GDM is that it results in costly expansion of the population of women diagnosed with this abnormality, whereas treatments that can be offered have insufficient or uncertain effectiveness.
The current therapeutic paradigm is based on the premise that tight glycaemic control during pregnancy is of utmost importance. However, it was reported from several countries that reaching currently recommended goals does not substantially reduce the proportion of macrosomic outcomes in pregnant patients with T1DM. Thus, the criteria for glycaemic control, use of monitoring tools and treatment methods in pre-gestational diabetes should be further discussed. Finally, whereas insulin therapy is the only approved pharmacological treatment during pregnancy, further debate is necessary on whether oral hypoglycaemic agents, such as sulphonylurea and metformin, constitute an alternative in specific patient groups, such as patients with GDM and monogenic diabetes.
